Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis

Figures & data

Table 1. Demographic characteristics of commercially insured patients with NCFB and exacerbations.

Characteristics	NCFB		NCFB with exacerbations with P. aeruginosa		NCFB with exacerbations without P. aeruginosa
	n = 36,283		n = 1,180		n = 18,074
Gender, n (%) Female	22,960	63.28%	654	55.42%	11,033	61.04%
Age (years), Mean, SD	53.7	9.85	53.23	10.72	53.27	10.11
Benefit Plan, n (%)
HMO	7,384	20.35%	239	20.25%	3,277	19.34%
PPO	25,285	69.69%	837	70.93%	11,894	70.19%
POS	2,127	5.86%	57	4.83%	1,067	6.30%
Other/Unknown	1,487	4.01%	47	3.99%	1,836	10.15%
Charlson Comorbidity
Index Score, Mean, SD	2.16	1.89	2.86	2.17	2.44	2.08

Abbreviations: NCFB, Non-cystic Fibrosis Bronchiectasis; SD, Standard Deviation; HMO, Health management organization; PPO, Preferred provider organization; POS, Point of service.

Figure 1. Antibiotic prescription fills PPPY patients with NCFB and exacerbations.

Abbreviations: IV, intravenous; PA, Pseudomonas aeruginosa.

Figure 2. Inpatient encounters PPPY for patients with NCFB and exacerbations.

Abbreviations: IV, intravenous; PA, Pseudomonas aeruginosa; IP, inpatient.

Figure 3. Outpatient encounters PPPY for patients with NCFB and exacerbations.

Abbreviations: IV, intravenous; PA, Pseudomonas aeruginosa.

Figure 4. Costs by service PPPY for patients with NCFB and exacerbations.

Abbreviations: IV, intravenous; PA, Pseudomonas aeruginosa.